Acromegaly - Symptoms, Causes, Treatment & Prevention

Overview

Acromegaly is a chronic hormonal disorder that results from excess production of growth hormone (GH) after the epiphyseal growth plates have closed, usually caused by a benign tumor of the pituitary gland (most often a somatotroph adenoma). The surplus GH stimulates the liver to release insulin‑like growth factor‑1 (IGF‑1), leading to progressive enlargement of bones and soft tissues.

It most commonly affects adults between the ages of 30 and 50, but it can occur at any age. Women and men are affected roughly equally.

According to the CDC and the Mayo Clinic, the prevalence of acromegaly is about 40–70 cases per million people worldwide, with an incidence of 3–4 new cases per million per year. Because the disease develops slowly, diagnosis is often delayed by 5–10 years from symptom onset.

Symptoms

Symptoms develop gradually and may be subtle at first. They reflect both the direct effects of excess GH and the downstream effects of high IGF‑1.

Physical changes

• Enlarged hands and feet: Ring size may increase, shoes become tight.
• Facial bone growth: Prominent brow ridge, protruding jaw (prognathism), enlarged nose, thickened lips.
• Skin changes: Thick, oily, and sweaty skin; development of skin tags.
• Soft‑tissue swelling: Especially around the tongue (macroglossia) and gums.

Metabolic and systemic symptoms

• Headaches: Often due to tumor pressure.
• Visual disturbances: Bitemporal hemianopsia from compression of the optic chiasm.
• Joint pain and arthropathy: Cartilage overgrowth leads to arthritis.
• Sleep apnea: Enlarged soft tissues narrow the airway.
• Excessive sweating and heat intolerance.
• Fatigue and muscle weakness.
• Hypertension, glucose intolerance or type 2 diabetes.
• Cardiomyopathy: Thickened heart walls (concentric hypertrophy).

Psychosocial impact

• Changes in appearance can lead to anxiety, depression, and social withdrawal.
• Reduced quality of life scores are documented in up to 70 % of patients before treatment (NIH).

Causes and Risk Factors

Primary cause

The vast majority of cases (>95 %) stem from a pituitary adenoma that secretes excess GH. These tumors are usually benign (non‑cancerous) but can grow large enough to cause mass effects.

Other, less common causes

• Ectopic GH‑secreting tumors (e.g., bronchial carcinoids).
• Hypothalamic disorders that reduce somatostatin inhibition.

Risk factors

• Age: Most diagnoses occur between 30–50 years.
• Gender: Slightly higher detection in women due to cosmetic concerns.
• Family history of pituitary tumors: Rare genetic syndromes (e.g., MEN‑1, Carney complex).
• Radiation exposure: Prior cranial irradiation increases adenoma risk.

Diagnosis

Because symptoms evolve slowly, a high index of suspicion is essential. Diagnosis combines clinical assessment, biochemical testing, and imaging.

Biochemical tests

1. IGF‑1 level: Elevated IGF‑1, adjusted for age and sex, is the most reliable screening test (Mayo Clinic).
2. Oral glucose tolerance test (OGTT) for GH suppression: In normal individuals, GH falls < 1 µg/L after a 75‑g glucose load. Failure to suppress (< 1 µg/L) confirms autonomous GH secretion.
3. Additional hormone panels: May reveal co‑secretion of prolactin, ACTH, or TSH.

Imaging studies

• Magnetic Resonance Imaging (MRI): Preferred modality; detects micro‑ (<10 mm) and macro‑adenomas, assesses cavernous sinus invasion.
• CT scan: Used when MRI is contraindicated.

Other assessments

• Visual field testing (perimetry) to detect chiasmal compression.
• Cardiovascular evaluation (echocardiogram, ECG) because of increased cardiac risk.
• Sleep study if obstructive sleep apnea is suspected.

Treatment Options

Therapy aims to normalize GH/IGF‑1 levels, reduce tumor size, alleviate symptoms, and prevent complications. A multidisciplinary team (endocrinology, neurosurgery, radiology, dentistry, and psychology) is ideal.

1. Surgical treatment

• Transsphenoidal pituitary surgery: First‑line for most patients; success (GH remission) rates 50–70 % for microadenomas and 30–50 % for macroadenomas (Cleveland Clinic).
• Potential complications: CSF leak, hypopituitarism, diabetes insipidus.

2. Medication

• Somatostatin analogues (SSA): Octreotide, lanreotide, and the long‑acting pasireotide. Reduce GH secretion by ~50–70 % and may shrink tumors.
• Growth hormone receptor antagonist: Pegvisomant blocks peripheral IGF‑1 production; normalizes IGF‑1 in >90 % of patients but does not affect tumor size.
• Dopamine agonists: Cabergoline or bromocriptine are useful when prolactin co‑secretion exists or in mild disease.
• Therapeutic choice depends on tumor size, GH/IGF‑1 levels, comorbidities, and patient preference.

3. Radiation therapy

• Conventional fractionated radiotherapy: Takes 5–10 years for hormonal control; risk of hypopituitarism.
• Stereotactic radiosurgery (Gamma Knife, CyberKnife): Delivers focused high‑dose radiation; achieves control in 50–70 % within 5 years with lower risk of surrounding tissue damage.

4. Lifestyle and supportive measures

• Weight management and regular aerobic exercise to improve insulin sensitivity.
• Low‑sodium diet and adequate hydration to help control hypertension.
• Dental care: regular visits for enlarged jaw and tongue issues.
• Sleep hygiene and CPAP therapy if sleep apnea is present.
• Psychological counseling or support groups to address body‑image concerns.

Living with Acromegaly

Even after biochemical remission, many patients experience lasting physical changes. Practical strategies can improve daily life.

Self‑monitoring

• Track IGF‑1 levels as recommended by your endocrinologist (usually every 6–12 months).
• Monitor blood pressure, fasting glucose, and weight.
• Keep a symptom diary—note new joint pain, visual changes, or sleep disturbances.

Joint and bone health

• Low‑impact activities (swimming, cycling) reduce joint strain.
• Physical therapy focusing on range‑of‑motion and strengthening exercises.
• Calcium (1,000–1,200 mg/day) and vitamin D (800–1,000 IU/day) supplementation as advised.

Dental and oral care

• Visit a dentist experienced with macroglossia and prognathism at least twice a year.
• Consider orthodontic or surgical correction for severe jaw enlargement.

Work and social life

• Explain accommodations (e.g., ergonomic tools) to employers if joint pain limits manual tasks.
• Join patient advocacy groups such as the Acromegaly Community or the Pituitary Foundation for peer support.

Emotional well‑being

• Seek counseling if you experience depression or anxiety.
• Mindfulness, yoga, and stress‑reduction techniques have been shown to improve quality of life (NIH, 2022).

Prevention

Because acromegaly is typically caused by a spontaneous pituitary adenoma, primary prevention is limited. However, risk reduction strategies include:

• Avoid unnecessary cranial radiation: Use modern, targeted techniques when radiation is medically required.
• Screen high‑risk groups: Patients with known genetic syndromes (MEN‑1, Carney complex) should undergo periodic pituitary imaging.
• Early medical evaluation: Prompt assessment of unexplained headaches, visual changes, or progressive enlargement of hands/feet can catch disease earlier.

Complications

If untreated or poorly controlled, excess GH/IGF‑1 can lead to serious, sometimes life‑threatening problems:

• Cardiovascular disease: Hypertension, left‑ventricular hypertrophy, arrhythmias, and increased risk of myocardial infarction (mortality up to 2‑3 times higher).
• Respiratory issues: Obstructive sleep apnea and restrictive lung disease.
• Metabolic disorders: Type 2 diabetes mellitus or impaired glucose tolerance.
• Arthropathy: Severe osteoarthritis requiring joint replacement.
• Colon polyps and cancer: Slightly increased prevalence; colonoscopy recommended every 5 years after diagnosis.
• Vision loss: From optic chiasm compression.
• Pituitary insufficiency: Hormone deficiencies after tumor growth or treatment.

When to Seek Emergency Care

Key Takeaways

• Acromegaly is rare but serious; early detection prevents irreversible complications.
• Biochemical testing (IGF‑1, GH suppression) plus MRI are the diagnostic cornerstones.
• Transsphenoidal surgery, medical therapy (SSA, pegvisomant, dopamine agonists), and focused radiation together provide high rates of disease control.
• Long‑term follow‑up, lifestyle adjustments, and psychosocial support are essential for quality of life.

For personalized guidance, schedule an appointment with an endocrinologist experienced in pituitary disorders. Reliable information can also be found at the Mayo Clinic, CDC, NIH, and the World Health Organization.